Discussion about this post

User's avatar
Ryan's avatar

Preach!

Expand full comment
Sarah Dean's avatar

To your point about potential flaws in randomized studies, the ultimate takeaway for hormone replacement therapy is not so easily inferred from the results of WHI's randomized control trial. A recent NYT piece argues against the now common wisdom that the costs of treatment outweigh the benefits -- both because the scientifically measured "benefits" are narrow in scope compared with women's experiences, and because the focus on /post/ menopausal women misses a key demographic:

> The study itself was designed with what would come to be seen as a major flaw. W.H.I. researchers wanted to be able to measure health outcomes — how many women ended up having strokes, heart attacks or cancer — but those ailments may not show up until women are in their 70s or 80s. The study was scheduled to run for only 8½ years. So they weighted the participants toward women who were already 60 or older. That choice meant that women in their 50s, who tended to be healthier and have more menopausal symptoms, were underrepresented in the study.

https://www.nytimes.com/2023/02/01/magazine/menopause-hot-flashes-hormone-therapy.html

Expand full comment
12 more comments...

No posts